Zolgensma, a gene therapy that can transform the lives of children with spinal muscular atrophy, carries a record $2 million price tag per dose. Although early development was funded by taxpayers and small charities, most of the financial rewards have gone to executives, investors and a pharmaceutical company. Its high cost contributes to rising drug spending in the U.S. and makes the treatment largely inaccessible in many lower-income countries.
